Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Repinatrabit in Hepatic or Renal Impairment
NCT07713758Phase 1Recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of repinatrabit in phenylketonuria (PKU) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoints: Area Under the Concentration-Time Curve Calculated to the Last Observable Concentration at Time t, Area Under the Concentration-Time Curve From Time Zero to Infinity and 1 more. Started Jul 2026; status: recruiting.
02
Drugs
repinatrabit
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT07713758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07713758.